Loading...
Loading...
EXAS| Name | Value |
|---|---|
| Revenues | 646.9M |
| Cost of Revenue | 171.8M |
| Gross Profit | 475.1M |
| Operating Expense | 542.9M |
| Operating I/L | -67.8M |
| Other Income/Expense | 25.3M |
| Interest Income | -6,269.6M |
| Pretax | -50.4M |
| Income Tax Expense | -0.6M |
| Net Income/Loss | -49.8M |
Exact Sciences Corporation is a leading provider of cancer screening and diagnostic test products, specializing in non-invasive solutions. Their flagship product, Cologuard, is a stool-based DNA screening test for colorectal cancer and pre-cancer detection. The company also offers a range of gene expression tests for breast, prostate, and colon cancers, as well as Covid-19 testing services. With a focus on enhancing the performance of their existing products and developing new fluid-based tests, Exact Sciences generates revenue through the sale of these innovative screening and diagnostic solutions.
